Q2 2024 Praxis Precision Medicines Inc Earnings Call Transcript
Key Points
- Praxis Precision Medicines Inc (PRAX) has made significant progress in 2024, positioning up to four programs in the registrational phase by 2025.
- The company is fully funded through several key readouts, with a strong cash position of $433.8 million, ensuring financial stability into 2027.
- The Essential3 trials for Ulixacaltamide in essential tremor are progressing well, with topline results expected later this year.
- The PRAX-628 program in epilepsy is advancing with multiple studies, including the RADIANT study, which is expected to provide important safety, PK, and efficacy information.
- The EMBOLD Study of relutrigine (PRAX-562) in pediatric patients with developmental and epileptic encephalopathies is on track, with topline results expected this quarter.
- Operating expenses increased to $37.8 million in Q2, up from $20.9 million in Q1, reflecting higher activity levels.
- The Essential3 trials for Ulixacaltamide may face potential delays if an interim analysis necessitates an increase in sample size.
- The company acknowledges the challenges and uncertainties associated with being the first in the essential tremor space, which could impact the success of their programs.
- The RADIANT study for PRAX-628 is not placebo-controlled, which may limit the robustness of the efficacy data compared to the POWER1 and POWER2 studies.
- The EMBOLD Study involves very severe patients, which could complicate the interpretation of efficacy and safety results.
Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' second-quarter 2024 corporate update conference call. (Operator Instructions) Please note that today's conference is being recorded.
I will now hand the conference over to your speaker host, Daniel Ferry. Please go ahead.
Good morning and welcome to Praxis Precision Medicine's second quarter 2024 Financial Results and Business Update Conference Call. This call is being webcast live and can be accessed on the Investors section of Praxis' website at www.praxismedicines.com. This call is also being recorded.
Please note that remarks made during this call may contain forward-looking statements within the meeting of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
